AI drug discovery momentum continued with an $888 million R&D collaboration between Insilico Medicine and Servier to identify oncology candidates, and publication of PEGASUS by AI biotech 1910, an AI model for designing cell‑permeable macrocyclic peptides. Insilico will combine its Pharma.AI platform with Servier’s development capabilities; the deal includes upfront and milestone payments. 1910’s PEGASUS model, described in the Journal of Medicinal Chemistry, reported the first cyclic peptides with multiple polar fragments that achieve in‑vitro membrane permeability, expanding modalities for intracellular targets. Together, the deals and publications underscore accelerating industry investment in generative and predictive models for challenging target classes.